

This document applies to the following:

Formulary	Applies
Standard Control (SF)	<input checked="" type="checkbox"/>
Standard Control – Choice (SCCF)	<input checked="" type="checkbox"/>
Preferred Drug Plan Design (PDPD)	<input type="checkbox"/>
Advanced Control Specialty (ACSF)	<input checked="" type="checkbox"/>
Advanced Control Specialty – Choice (ACSCF)	<input checked="" type="checkbox"/>
Managed Medicaid Template (MMT)	<input type="checkbox"/>
Marketplace (MF)	<input checked="" type="checkbox"/>
Aetna Small Group Affordable Care Act (SG ACA)	<input checked="" type="checkbox"/>
Aetna Health Exchange (AHE)	<input checked="" type="checkbox"/>
Aetna Individual Lives (IVL)	<input checked="" type="checkbox"/>
Value (VF)	<input checked="" type="checkbox"/>

Formulary	Applies
New to Market (NTM)	<input type="checkbox"/>
Standard Formulary Chart (SFC)	<input checked="" type="checkbox"/>
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	<input type="checkbox"/>
Advanced Control Specialty Formulary Chart (ACSFC)	<input checked="" type="checkbox"/>
Value Formulary Chart (VFC)	<input checked="" type="checkbox"/>
Medical Benefit	<input type="checkbox"/>
Medical Benefit: Advanced Biosimilars First	<input type="checkbox"/>
Medical Benefit: Managed Medicaid (MMMB)	<input type="checkbox"/>
Medicare Part B	<input type="checkbox"/>
Medicare Part B: Advanced Biosimilars First	<input type="checkbox"/>

Exceptions Criteria

Colony Stimulating Factors – Long Acting

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Standard Control Formulary (SF), Standard Control Choice Formulary (SCCF), Advanced Control Specialty Formulary (ACSF), Advanced Control Specialty – Choice Formulary (ACSCF), Marketplace Formulary (MF), Small Group Affordable Care Act (ACA) Aetna Health Exchange (AHE), Aetna Individual Lives (IVL) Formulary, Value Formulary (VF), Value Formulary Chart (VFC), Advanced Control Specialty Formulary Chart (ACSFC), and Standard Control Formulary Chart (SFC).

Plan Design Summary

This program applies to the long-acting colony stimulating factor products specified in this document. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with a targeted product.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Colony Stimulating Factors – Long Acting

Medications considered formulary or preferred on your plan may still require a clinical prior authorization

Specialty Exceptions CSF-Long Acting SF-SCCF-ACSF-ACSCF-VF-MF-ACSFC-SFC-VFC-IVL-AHE 5906-D P2025a_R.docx© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

review.

	Products
Preferred	<ul style="list-style-type: none"> Fylnetra (pegfilgrastim-pbbk) Nyvepria (pegfilgrastim-apgf)
Target	<ul style="list-style-type: none"> Fulphila (pegfilgrastim-jmdb) Neulasta (including Onpro kit) (pegfilgrastim) Rolvedon (eflapeggrastim-xnst) Stimufend (pegfilgrastim-fpgk) Udenyca (pegfilgrastim-cbqv) Ziextenzo (pegfilgrastim-bmez)

Exception Criteria

Coverage for the targeted products is provided when the member has had a documented intolerable adverse event to all of the preferred products and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).

References

1. Neulasta [package insert]. Thousand Oaks, CA: Amgen, Inc.; February 2021.
2. Fulphila [package insert]. Cambridge, MA: Biocon Biologics Inc.; June 2023.
3. Fylnetra [package insert]. Piscataway, NJ: Kashiv BioSciences, LLC; May 2022.
4. Nyvepria [package insert]. Lake Forest, IL: Hospira, Inc.; March 2023.
5. Rolvedon [package insert]. Lake Forest, IL: Spectrum Pharmaceuticals, Inc.; November 2023.
6. Stimufend [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2023.
7. Udenyca [package insert]. Redwood City, CA: Coherus BioSciences, Inc.; December 2023.
8. Ziextenzo [package insert]. Princeton, NJ: Sandoz Inc.; February 2024.